Is MD a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for Pediatrix Medical Group (MD) rests on Pricing and reimbursement strength: Pediatrix has been generating same-unit revenue growth through pricing gains of around 4%, supported by strong revenue-cycle cash collections, higher contract administrative fees from hospital partners and a slightly favorable payer mix. Revenue (TTM) is ~$1.93B. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Portfolio restructuring and practice divestitures continue to pressure headline revenue and narrow revenue diversification in a sector with several large, well-capitalized competitors. Whether MD is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Pediatrix Medical Group (NYSE: MD), founded in 1979 and known as MEDNAX until its 2022 rebrand, provides hospital-based physician staffing and clinical services concentrated in neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and related anesthesiology support. Its clinicians largely staff neonatal intensive care units and other hospital departments under contracts with hospital partners, with revenue driven by patient volumes, payer reimbursement, contract administrative fees and revenue-cycle collections. The investment picture is one of a mature, low-multiple services business working through a deliberate simplification. Recent results show revenue and margins improving on the strength of pricing (roughly 4% in Q1 2026), better collections, higher administrative fees and increased neonatology acuity, even as patient volumes across service lines drift modestly lower. Management has been divesting non-core practices to sharpen focus on core women's and children's services, improve profitability and pay down debt, which shrinks the revenue base but is intended to lift quality of earnings. The stock trades at a meaningful discount to healthcare-sector peers, reflecting both the restructuring drag and the cost pressures typical of physician-staffing models.
What's the case for buying MD?
1. Pricing and reimbursement strength
Pediatrix has been generating same-unit revenue growth through pricing gains of around 4%, supported by strong revenue-cycle cash collections, higher contract administrative fees from hospital partners and a slightly favorable payer mix. Increased patient acuity, particularly in neonatology, has helped net reimbursement per case. This pricing engine has been the main offset to soft volumes.
2. Portfolio simplification and debt paydown
The company has divested non-core practices to concentrate on core women's and children's services. The strategy narrows the revenue base but is aimed at improving profitability, simplifying operations and reducing debt. If executed cleanly, it can lift margins and quality of earnings even without top-line growth.
3. Margin and EBITDA recovery
Operating margin expanded in early 2026 (to roughly 8.7% in Q1 from 7.0% a year earlier) and management reaffirmed a full-year adjusted EBITDA range of about $280 million to $300 million. Continued cost discipline against physician compensation is central to hitting the midpoint near $290 million.
4. Low valuation relative to peers
MD trades at a low-teens price-to-earnings multiple versus roughly 20x-plus for healthcare peers, which some value-oriented observers read as a discount. That gap reflects skepticism about growth and restructuring risk, so any narrowing depends on demonstrated, durable margin repair.
What are the risks to MD?
Portfolio restructuring and practice divestitures continue to pressure headline revenue and narrow revenue diversification in a sector with several large, well-capitalized competitors. Physician compensation, salaries and staffing costs can squeeze already tight margins if pricing gains slow. Patient volumes have been declining in parts of the business, including maternal-fetal medicine and neonatology, so growth leans heavily on pricing and payer mix rather than demand. The business is exposed to government and commercial reimbursement policy, hospital-contract renewals and concentration in a small set of subspecialties. Any reversal in payer mix or collections would hit results quickly given the thin operating margins.
How is MD valued? (as of July 2026)
Snapshot for MD as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$1.93B
- Q1 2026 net revenue: ~$476M
- Net margin (TTM): ~9%
- P/E ratio: ~12x
- FY2026 adj. EBITDA guidance: ~$280M-$300M
- FY2026 EPS estimate: ~$2.14
Pediatrix trades at a low-teens price-to-earnings multiple, well below the roughly 20x-plus average for healthcare-services peers, which reflects modest growth expectations and restructuring drag. Q1 2026 revenue rose about 4% year on year to roughly $476 million while diluted EPS improved to about $0.36 from $0.24. Full-year adjusted EBITDA is guided near $290 million at the midpoint.
How do you decide if MD is a buy?
Rather than asking whether MD is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold MD indirectly through an index or sector ETF before adding more.
For the full picture, see the MD stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about MD against your real portfolio and see your actual exposure before deciding.
The bottom line on MD
The bottom line: Pediatrix Medical Group's story right now is Pricing and reimbursement strength, with revenue (ttm) at ~$1.93B. If you believe that narrative continues, the call is about sizing MD sensibly and checking overlap with what you own; if you doubt it (the risk: portfolio restructuring and practice divestitures continue to pressure headline revenue and narrow revenue diversification in a sector with several large, well-capitalized competitors.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
More on MD
- MD stock guide (what the company does, ETFs that hold it, similar stocks, and the themes it fits)
- MD stock forecast (the drivers and risks shaping the outlook)
- Does MD pay a dividend?
Build a basket around MD with Walnut
Use Pediatrix Medical Group as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is MD a good stock to buy right now?
+
The case for Pediatrix Medical Group right now is Pricing and reimbursement strength, with revenue (ttm) at ~$1.93B. If you believe that thesis holds, MD is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is portfolio restructuring and practice divestitures continue to pressure headline revenue and narrow revenue diversification in a sector with several large, well-capitalized competitors. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Pediatrix Medical Group do?
+
Pediatrix Medical Group (NYSE: MD), founded in 1979 and known as MEDNAX until its 2022 rebrand, provides hospital-based physician staffing and clinical services concentrated in neo
What are the main risks of MD?
+
Portfolio restructuring and practice divestitures continue to pressure headline revenue and narrow revenue diversification in a sector with several large, well-capitalized competitors. Physician compensation, salaries and staffing costs can squeeze already tight margins if pricing gains slow. Patient volumes have been declining in parts of the business, including maternal-fetal medicine and neonatology, so growth leans heavily on pricing and payer mix rather than demand. The business is exposed to government and commercial reimbursement policy, hospital-contract renewals and concentration in a small set of subspecialties. Any reversal in payer mix or collections would hit results quickly given the thin operating margins.
What does Pediatrix Medical Group do?
+
Pediatrix provides hospital-based physician services concentrated in neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and related anesthesiology. Its clinicians largely staff neonatal intensive care units and other hospital departments under partner contracts.
Why was Pediatrix formerly called MEDNAX?
+
The company was founded in 1979 and operated for years as MEDNAX. It rebranded to Pediatrix Medical Group in 2022 to reflect its sharpened focus on core women's and children's services after divesting non-core lines.
How did Pediatrix perform in Q1 2026?
+
Q1 2026 net revenue rose to roughly $476 million from about $458 million, up around 4% year on year. Net income increased to about $29.6 million and diluted EPS improved to roughly $0.36 from $0.24, with operating margin near 8.7%.
Why is the stock cheap relative to peers?
+
MD trades at a low-teens P/E versus roughly 20x-plus for healthcare peers. The discount reflects slow growth, declining patient volumes in some lines and the revenue drag from ongoing portfolio restructuring, which the market weighs against improving margins.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell MD; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.